LB Pharmaceuticals, Inc. - LBRX Enterprise Value-to-Revenue Ratio

Public company logo of lbpharma.us (LBRX)

The psychopharmacology sector remains independent of macroeconomics, serving as a reliable defensive asset. The price-to-sales ratio on the GURU.Markets chart helps track this trend, where 0.00 determines the current status of the parameter. LB Pharmaceuticals Inc (LBRX) develops small molecules for the treatment of schizophrenia, however, the absence of sales makes the business entirely dependent on existing cash reserves.

LB Pharmaceuticals, Inc. - LBRX Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

LB Pharmaceuticals, Inc. - analytical breakdowns and key metrics (LBRX)

Initial company analysis:lbpharma.us LBRX
Product sample of LB Pharmaceuticals

This indicator determines the objective value of the business by excluding the impact of leverage on the valuation. It compares the total enterprise value with the volume of generated revenue, revealing the actual efficiency of asset capitalization. By analyzing the EV/Sales multiple of the company, an investor assesses the premium paid per unit of revenue. For LB Pharmaceuticals Inc (LBRX), this is critical, as the modification of psychotropic agents accelerates commercialization. The metric reflects market expectations for profits from new drugs.